EcoDrugPlus

Adenosine Deaminase

Ensembl ID : ENSMLUG00000016178
Gene Symbol: ADA
2 Cross references
216 Possible Orthologues:

Adrenoceptor Alpha 1a

Ensembl ID : ENSMLUG00000027812
Gene Symbol: ADRA1A
2 Cross references
201 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSMLUG00000010123
Gene Symbol: ADRA1B
2 Cross references
263 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSMLUG00000024223
Gene Symbol: ADRA1D
2 Cross references
194 Possible Orthologues:

Adrenoceptor Alpha 2b

Ensembl ID : ENSMLUG00000023263
Gene Symbol: ADRA2B
2 Cross references
219 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSMLUG00000006314
Gene Symbol: ADRB2
2 Cross references
263 Possible Orthologues:

Adrenoceptor Beta 3

Ensembl ID : ENSMLUG00000007514
Gene Symbol: ADRB3
4 Cross references
215 Possible Orthologues:

Advanced Glycosylation End-Product Specific Receptor

Ensembl ID : ENSMLUG00000000533
Gene Symbol: AGER
2 Cross references
169 Possible Orthologues:

Alcohol Dehydrogenase 5 (Class Iii), Chi Polypeptide

Ensembl ID : ENSMLUG00000002722
Gene Symbol: ADH5
4 Cross references
401 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSMLUG00000007270
Gene Symbol: AKR1B1
2 Cross references
427 Possible Orthologues:

Alpha Glucosidase

Ensembl ID : ENSMLUG00000009543
Gene Symbol: GAA
2 Cross references
234 Possible Orthologues:

Amiloride-Sensitive Amine Oxidase [Copper-Containing]-Like

Ensembl ID : ENSMLUG00000023728
Gene Symbol: LOC102429790
3 Cross references
226 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).